Peginterferon alfa-2b (Y-shaped pegylation) - Xiamen Amoytop Biotech

Drug Profile

Peginterferon alfa-2b (Y-shaped pegylation) - Xiamen Amoytop Biotech

Alternative Names: Y-shaped pegylated interferon alfa-2b; YPEG-rhIFNα-2b - Xiamen Amoytop Biotech; Ypeginterferon alfa-2b - Xiamen Amoytop Biotech; Ypeginterferon alpha-2b - Xiamen Amoytop Biotech

Latest Information Update: 06 Oct 2015

Price : $50

At a glance

  • Originator Xiamen Amoytop Biotech
  • Class Antineoplastics; Antivirals; Interferons; Polyethylene glycols
  • Mechanism of Action Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hepatitis B; Hepatitis C

Most Recent Events

  • 01 Aug 2015 Xiamen Amoytop Biotech completes a phase III trial for Hepatitis B in China (NCT01760122)
  • 30 Jun 2014 Phase-II clinical trials in Hepatitis B (Combination therapy) in China (SC)
  • 30 Jun 2014 Xiamen Amoytop Biotech completes enrolment in its phase III trial for Hepatitis B in China (NCT01760122)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top